Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267488 · ClinicalTrials.gov registry record · Phase 2
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
A Phase 2 study of Endometrial Cancer and Neoplasms, Endometrial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT00267488: Completed Phase 2 study of Endometrial Cancer and Neoplasms, Endometrial, sponsored by GlaxoSmithKline.
NCT00267488 is a Phase 2 study of Endometrial Cancer and Neoplasms, Endometrial that has completed, run by GlaxoSmithKline. The registered enrollment target is 70 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00267488, a Phase 2 study of Endometrial Cancer and Neoplasms, Endometrial, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
Primary Outcome
Tumor response based on GOG (Gynecological Oncology Group) modified RECIST (Response Evaluation Criteria In Solid Tumors) criteria. A 4-point scale used specifying tumor response. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions; (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; (PD): At least a 20% increase in the sum of the LD of target lesions
Conditions Studied
Interventions
- DRUG topotecan
Study Locations (20)
Florida
- GSK Investigational Site - Coral Gables
- GSK Investigational Site - Lakeland
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
California
- GSK Investigational Site - La Jolla
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Newport Beach
Illinois
- GSK Investigational Site - Chicago
- GSK Investigational Site - Hinsdale
South Carolina
- GSK Investigational Site - Columbia
- GSK Investigational Site - Greenville
Tennessee
- GSK Investigational Site - Chattanooga
- GSK Investigational Site - Knoxville
Colorado
- GSK Investigational Site - Engelwood
Georgia
- GSK Investigational Site - Atlanta
Louisiana
- GSK Investigational Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00267488 record still lists
NCT00267488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which topotecan is the first listed.
NCT00267488 names 20 study sites across 12 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00267488 about?
NCT00267488 is a clinical study titled "Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer". The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
What is the current status of trial NCT00267488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-10. Estimated completion is 2007-12.
What conditions does trial NCT00267488 study?
This clinical trial studies the following conditions: Endometrial Cancer, Neoplasms, Endometrial.
What interventions are being tested in trial NCT00267488?
The interventions under investigation include: topotecan (DRUG).
Who is sponsoring clinical trial NCT00267488?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00267488 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00267488's enrollment target sits among peer trials
70 105th of 181 higher than 72 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia